Abstract:BACKGROUND:An intimidating challenge to transporting drugs into the brain parenchyma is the presence of the blood-brain barrier (BBB). Glucose is an essential nutritional substance for brain function sustenance, which cannot be synthesized by the brain. Its transport primarily depends on the glucose transporters on the brain capillary endothelial cells. In this paper, the brain-targeted properties of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers were compared and evaluated to establish an optimized drug-delivery system. METHODS:Coumarin 6-loaded liposomes (GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-LIP) composed of phospholipids and glucose-derived cholesterols were prepared by thin-film dispersion-ultrasound method. The BBB model in vitro was developed to evaluate the transendothelial ability of the different liposomes crossing the BBB. The biodistribution of liposomes in the mice brains was identified by in vivo and ex vivo nearinfrared fluorescence imaging and confocal laser scanning microscopy and further analyzed quantitatively by high-performance liquid chromatography. RESULTS:Glucose-derived cholesterols were synthesized and identified, and coumarin 6-loaded liposomes were prepared successfully. The particle sizes of the four types of glucose-modified liposomes were around or smaller than 100 nm with a polydispersity index less than 0.300. GLU400-LIP, GLU1000-LIP, and GLU2000-LIP achieved higher cumulative cleared volumes on BBB model in vitro after 6 hours compared with GLU200-LIP (P < 0.05) and were significantly higher than that of the conventional liposome (P < 0.001). The qualitative and quantitative biodistribution results in the mice showed that the accumulation of GLU1000-LIP in the brain was the highest among all the groups (P < 0.01 versus LIP). CONCLUSION:The data indicated that GLU400-LIP, GLU1000-LIP, and GLU2000-LIP all possess the potential of brain targeting, among which GLU1000-LIP, as a promising drug-delivery system, exhibited the strongest brain delivery capacity.

Design, Synthesis and Biological Evaluation of Multivalent Glucosides with High Affinity As Ligands for Brain Targeting Liposomes.

Design, Synthesis and Biological Evaluation for Docetaxel- Loaded Brain Targeting Liposome with "Lock-In'' Function

Synthesis of Multivalent Glucosides with High Affinity for GLUT1 Transporter

Design, Synthesis And In Vivo Evaluation Of Sulfhydryl Beta-D-Glucose Cholesterols As Ligands For Brain Targeting Liposomes

Dual-targeting for Brain-Specific Liposomes Drug Delivery System: Synthesis and Preliminary Evaluation

In Vitro and in Vivo Investigation of Glucose-Mediated Brain-Targeting Liposomes.

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

Biotin and Glucose Co-Modified Multi-Targeting Liposomes for Efficient Delivery of Chemotherapeutics for the Treatment of Glioma

Liposomes Actively Recognizing the Glucose Transporter GLUT(1) and Integrin Alpha(v)beta(3) for Dual-Targeting of Glioma

Brain-targeted Drug Delivery by in Vivo Functionalized Liposome with Stable D-peptide Ligand.

Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery

Enhanced Brain Targeting of Tegafur Using Novel Lactyl Cholesterol Liposome As a Carrier

Ascorbic Acid-Modified Brain-Specific Liposomes Drug Delivery System with "Lock-In" Function.

Design and Synthesis of Glucose-Cholesterol As Ligand for Brain Targeting Liposomes

Development of Functional Docetaxel Nanomicelles for Treatment of Brain Glioma

Peptide-22 and Cyclic Rgd Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming Bbb and Bbtb

A Nanostructure of Functional Targeting Epirubicin Liposomes Dually Modified with Aminophenyl Glucose and Cyclic Pentapeptide Used for Brain Glioblastoma Treatment

Liposome Formulated with TAT-modified Cholesterol for Improving Brain Delivery and Therapeutic Efficacy on Brain Glioma in Animals

Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma

Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility.

Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery